Lefamulin Tablets and Viramune O/S
Determining the interaction of Lefamulin Tablets and Viramune O/S and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. Reduced therapeutic efficacy may occur. MANAGEMENT: Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. Reduced therapeutic efficacy may occur.
MANAGEMENT: Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Lefamulin Injection, Lefamulin, Lefamulin (oral/injection)
Generic Name: nevirapine
Brand name: Viramune, Viramune XR
Synonyms: Nevirapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lefamulin Tablets-Viramune Suspension
- Lefamulin Tablets-Viramune XR
- Lefamulin Tablets-Virasal
- Lefamulin Tablets-Virasal Topical
- Lefamulin Tablets-Viravan P
- Lefamulin Tablets-Viravan PDM
- Viramune O/S-Leflunomide
- Viramune O/S-Legatrin PM
- Viramune O/S-Lemtrada
- Viramune O/S-Lenalidomide
- Viramune O/S-Lenvatinib
- Viramune O/S-Lenvatinib Mesylate